Valitor Closes $28M Series B Financing
- Valitor, a Berkeley, CA-based biotechnology company, raised $28M in Series B funding
- The round was led by Morningside, with participation from First Spark Ventures, ExSight Ventures, Berkeley Catalyst Fund, and Pandect Bioventures
- The company intends to use the funds to support its programs in ophthalmology and vision-threatening diseases, utilizing its Multivalent Polymer technology platform that originated at U.C. Berkeley
- The company is leveraging its biopolymer technology to engineer medicines that optimize how and where disease mechanisms are targeted to produce the most significant clinical impact
- The company is initially focused on improving patient outcomes in ophthalmology and vision-threatening diseases
